Agotamiento Emocional Médicos sin Burnout
CUESTIONARIO DE LOS RASGOS DE PERSONALIDAD(EPQR-A) EN LAS ENFERMERAS
1. Parkinson’s disease patients should be regularly and carefully screened for depressive symptoms as part of their care. A simple, validated instrument such as the ZSDS can be used.
2. Adequate attention should be given to quality of life related matters during management of PD patients. Determinants identified to impact on PD HrQoL should also be specifically explored in each patient.
3. The standard of care in PD should include prompt treatment of depression as a potential modality improving quality of life, whilst other modalities including optimization of treatment are employed.
REFERENCES
1. de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006; 5:
525–35.
2. Okubadejo NU, Bower JH, Rocca WA, Maraganore DM. Parkinson’s disease in Africa: A Systematic Review of Epidemiologic and Genetic Studies. Mov Disord. 2006; 21: 2150–6.
3. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K et al.
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007; 68:384–6.
4. Fitzpatrick R, Peto V, Jenkinson C, Greenhall R, Hyman N. Health-related quality of life in Parkinson's disease: a study of outpatient clinic attenders. Mov Disord. 1997; 12: 916–22.
5. Reichmann H, Schneider C, Löhle M. Non-motor features of Parkinson’s disease: depression and dementia. Parkinsonism Relat Disord 2009; 15 Suppl 3: S87–92.
6. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson’s disease:
diagnosis and Management. Lancet Neurol 2006; 5: 235–45.
7. Lim SY and Lang AE. Non-motor Symptoms of Parkinson’s disease-An Overview. Mov Disord 2010; 25: Suppl 1: S123–30.
8. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non recognition of depression and other non-motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord. 2002; 8: 193–
7.
9. Weintraub D, Morales KH, Duda JE, Moberg PJ, Stern MB. Frequency and correlates of co-morbid psychosis and depression in Parkinson’s disease. Parkinsonism Relat Disord. 2006;
12: 427–31.
10. Dotchin CL, Jusabani A, Walker R.W. Non-motor symptoms in a prevalent population with Parkinson’s disease in Tanzania. Parkinsonism Relat Disord. 2009; 15: 457-60.
11. Ojo OO, Okubadejo NU, Ojini FI, Danesi MA. Frequency of cognitive impairment and depression in Parkinson’s disease: a preliminary case-control study. Nig Med Journ. 2012;
53: 65-70.
12. Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P et al. An international multicentre pilot study of the the first comprehensive self-completed non-motor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord. 2006;
21: 916 –23.
13. Bowling A. What things are important in people’s lives? A survey of the public’s judgements to inform scales of health related quality of life. Soc Sci Med. 1995; 41:1447–62.
14. Marinus J, Ramaker C, van Hilten JJ, Stiggelbout AM. Health related quality of life in Parkinson’s disease: a systematic review of disease specific instruments. J Neurol Neurosurg Psychiatry. 2002; 72: 241–8.
15. Lim SY and Lang AE. Non-motor Symptoms of Parkinson’s disease-An Overview. Mov Disord 2010; 25: Suppl 1: S123–30.
16. Cole SA, Woodard JL, Juncos JL, et al: Depression and disability in Parkinson’s disease. J Neuropsychiatry Clin Neurosc.i 1996; 8:20–25.
17. Okubadejo NU, Ojo OO, Oshinaike OO. Clinical profile of parkinsonism and Parkinson's disease in Lagos, Southwestern Nigeria. BMC Neurol. 2010; doi: 10.1186/1471-2377-10-1 18. Schoenberg BS, Osuntokun BO, Adeuja AO,Bademosi O, Nottidge V, Anderson DW, et al.
Comparison of the prevalence of Parkinson’s disease in black populations in the rural United States and in rural Nigeria: door-to-door community studies. Neurology. 1988; 38: 645– 6.
19. Parkinson J. Essay on the shaking palsy. Sherwood London: Neely and Jones; 1817.
20. Martinez-Martin P. , Schapira AH, Stocchi F, Sethi K, Odin P, MacPhee G et al. Prevalence of Nonmotor Symptoms in Parkinson’s Disease in an International Setting; Study Using Nonmotor Symptoms Questionnaire in 545 Patients. Mov Disord. 2007; 22(11): 1623–9
21. Global burden of neurologic disorders. Available at:
www.who.int/mental_health/neurology/chapter_2. neurodisorders public health challenges.
Accessed March 24 2011.
22. Okubadejo NU, Ojini FI, Danesi MA. Longitudinal study of mortality predictors in Parkinson’s disease in Nigerians. Afr Journ Med Sci. 2005; 34: 365-69
23. Hauser RA, Ahmed I, Blackmer J, Bloomfield SM, Campagnolo DI, Carroll TL et al.
Parkinson Disease. emedicine. Eds Benbadis SR et al. Available at:
http://emedicine.medscape.com/article/1831191-overview. Updated June 7 2011. Accessed June 10, 2011.
24. de Lau LML, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM. Incidence of parkinsonism and Parkinson disease in a general population. The Rotterdam Study.
Neurology. 2004; 63: 1240–4.
25. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology. 1999; 52: 1214-20 26. de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, et al.
Prevalence of parkinsonism and Parkinson's disease in Europe : the EUROPARKINSON Collaborative Study. Concerted Action on the Epidemiology of European Community disease. J Neurol Neurosurg Psychiatry. 1997; 62: 10-5.
27. Zhang ZX, Roman GC. Worldwide occurrence of Parkinson's disease: an updated review.
Neuroepidemiology.1993; 12: 195-208.
28. Attia Romhane N, Ben Hamida M, Mrabet A, Larnaout A, Samoud S, Ben Hamda A et al.
Prevalence study of neurologic disorders in Kelibia (Tunisia). Neuroepidemiology. 1993; 12:
285–99.
29. Ashok PP, Radhakrishnan K, Sridharan R, Mousa ME. Epidemiology of Parkinson's disease in Benghazi, North-East Libya. Clin Neurol Neurosurg. 1986; 88:109-13.
30. Dotchin C, Msuya O, Kissima J, Massawe J, Mhina A, Moshy A, et al. The Prevalence of Parkinson’s disease in Rural Tanzania. Mov Disord. 2008; 23: 1567-72.
31. Osuntokun BO, Adeuja AO, Schoenberg BS, Bademosi O, Nottidge VA, Olumide AO, et al.
Neurological disorders in Nigerian Africans: a community-based study. Acta Neurol Scand 1987; 75:13–21.
32. Greenamyre JT, Hastings TG. Biomedicine: Parkinson’s—divergent causes, convergent mechanisms. Science. 2004; 304: 1120–22.
33. Enza Maria Valente, Giuseppe Arena, Liliana Torosantucci, Vania Gelmetti. Molecular Pathways in Sporadic PD. Parkinsonism relat disord. 2012; 18:S1.71-73
34. Matsuda N, Tanaka K. Does impairment of the ubiquitin-proteasome system or the autophagy-lysosome pathway predispose individuals to neurodegenerative disorders such as Parkinson’s disease? J Alzheim Dis 2010; 19: 1-9
35. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003; 24: 197–211.
36. Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C. Genetic Etiology of Parkinson’s Disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2.
Genes: A Mutation Update.Human mutation. 2010; 31: 763–80.
37. Bekris LM, Mata IF, Zabetian CP. The genetics of Parkinson’s disease. J Geriatr Psychiatry Neurol. Dec 2010; 23: 228-42.
38. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of diagnosis of idiopathic Parkinson’s disease: a clinic-pathologic study of 100 cases. J Neurol Neurosurg Psychiatry. 1992; 55: 181-4.
39. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for PD. Arch Neurol. 1999; 56: 33-39.
40. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967; 17:
427–42.
41. Unified Parkinson’s Disease Rating Scale. Available at:
www.mdvu.org/library/ratingscales/pd/. Accessed June 8 2011.
42. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al.
Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Scale Presentation and Clinimetric Testing Results. Mov Disord.
2008; 23: 2129–70.
43. Muzerengia S, Contrafattoc D, Chaudhuri K. Non-motor symptoms: Identification and management. Parkinsonism Relat Disord. 2007; 13: S450–S456
44. Gallagher DA, Lees AJ, Schrag A. What are the most important non-motor symptoms in patients with Parkinson’s disease and are we missing them? Mov Disord. 2010; 25(15):
2493–500.
45. Aarsland D, Marsh L, Schrag A. Neuropsychiatric Symptoms in Parkinson’s disease
.
MovDisord .2009; 24:2175–86.
46. Okubadejo NU, Danesi MA. Frequency and predictors of autonomic dysfunction in Parkinson's disease: a study of African patients in Lagos, Nigeria. Niger Postgrad Med J.
2004; 11: 45-9.
47. Akinyemi RO, Okubadejo NN, Akinyemi JO, Owolabi MO, Owolabi LF, Ogunniyi A.
Cognitive dysfunction in Nigerians with Parkinson's disease. Mov Disord. 2008; 23: 1378-83.
48. Gómez-Esteban JC, Tijero B, Somme J, Ciordia R, Berganzo K, Rouco I, et al. Impact of psychiatric symptoms and sleep disorders on the quality of life of patients with Parkinson's disease. J Neurol. 2011; 258: 494-9.
49. Hantz, P, Caradoc-Davies T, Weatherall M, Dixon G. Depression in Parkinson’s disease. Am J Psychiatry 1994; 151: 1010-14
50. Reijnders JS, Ehrt U, WE, Aarsland D, and Leentjens AF. A Systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord. 2008; 23: 183–9.
51. Dissanayaka NN, Sellbach A, Matheson S, O'Sullivan, JD, Silburn PA, Byrne GJ, et al.
Anxiety disorders in Parkinson's disease: Prevalence and risk factors. Mov Disord. 2010; 25:
838–45.
52. Mayeux R. The ‘‘serotonin hypothesis’’ for depression in Parkinson’s disease. Adv Neurol.
1990; 53: 163–66.
53. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM IV). Washington, DC: American Psychiatric Association; 1994.
54. Schrag A, Barone P, Brown RG, Leentjens AF, McDonald WM, Starkstein S, et al.
Depression rating scales in Parkinson’s disease: critique and recommendations. Mov Disord.
2007; 22:1077–92.
55. Naarding P, Leentjens AF, Van Kooten F, Verhey FR. Disease-specific properties of the Hamilton Rating Scale for depression in patients with stroke, Alzheimer’s dementia, and Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 2002; 14: 329-34.
56. Leentjens AF, Marinus, J, Van Hilten JJ, R. Lousberg R, Verhey FR. The Contribution of somatic symptoms to the diagnosis of depressive disorder in Parkinson’s disease: A discriminant analytic approach. J Neuropsychiatry Clinl Neurosci. 2003; 15:74–7.
57. Zung WW: A self-rating depression scale. Arch Gen Psychiatry. 1965; 12: 63–70.
58. Shumway M, Sentell T, Unick G, Bamberg W. Cognitve complexity of self administered depression measures. J Affect Disord. 2004; 83: 191–8.
59. Okulate GT, Jones OB. Two depression rating instruments in Nigerian patients. Niger Postgrad Med J. 2002; 9: 74-8.
60. Sheik JI, Yesavage JA. Geriatric depression scale, GDS: recent evidence and development of a shorter version. Clin Gerontol. 1986; 165-73.
61. Yesavage JA,Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982; 17:37– 49.
62. Kanda F, Oishi K, Sekiguchi K, Kuga A, Kobessho H, Shirafuji T et al. Characteristics of depression in Parkinson’s disease: evaluating with Zung’s self rating depression scale.
Parkinsonism Relat Disord. 2008: 14, 19-23
63. Chagas M, Tunas Y, Lourerio S, Hallak J, Tresniak C. de Sousa J. validity of a Brazilian version of Zung self rating depression scale for the screening of depression in patients with Parkinson’s disease. Parkinsonism Relat Disord. 2010: 16, 42-45.
64. Lemke MR, Brecht HM, Koester J, Reichmann H. Effects of the dopamine agonist pramipexole on depression, anhedonia, and motor functions in Parkinson’s disease. J Neurol Sci. 2006; 248: 266–70.
65. Werner P. Depression in Parkinson’s disease. J Neurol. 2007; 254 (Suppl 5):49–55.
66. Okun MS, Watts RL. Depression associated with Parkinson’s disease: Clinical features and treatment. Neurology. 2002; 58 (S1): 63–70.
67. Gimenez-Roldan S, Dobato JL, Mateo D. Treatment of depression in Parkinson’s disease with moclobemide: A pilot open-label study. Parkinsonism Relat Disord. 1997; 3 (4):219–25.
68. WHOQOL group. The World Health Organization Quality of Life assessment (WHOQOL):
position paper from the World Health Organization. Soc Sci Med. 1995; 41: 1403–1409.) 69. World Health Organization. WHO Constitution: the first two chapters. Updated 27
September 1998. Available at: www.ldb.org/vl/top/whoconst.htm. Accessed June 10, 2011.
70. Brenda L, Den Oudsten, Guus L, Heck V and De Vries J. Quality of Life and Related Concepts in Parkinson’s Disease: A Systematic review. Mov disord. 2007; 22: 1528-37.
71. Karen H Karlsen, Elise Tandberg, Dag Arsland, Jan P Larsen. health related quality of life in Parkinsons disease patients, a prospective and longitudinal study. J Neurol Neurosug psychiatry. 2000; 69: 584-89
72. Leroi I, Ahearn DJ, Andrews M, McDonald K.R, Byrne JE, Burns A. Behavioral disorders, disability and quality of life in Parkinson’s disease. Age and Ageing. 2011; 40: 614-21.
73. Peto V, Jenkinson C, Fitzpatrick R: PDQ-39: a review of the development, validation and application of a Parkinson’s disease quality of life questionnaire and its associated measures.
J Neurol. 1998; 245(S1): 10–4.
74. Mutch WJ, Dingwell-fordyce I, Downie AW, Paterson JG, Roy SK. Parkinson disease in a Scottish city. BMJ. 1986; 292: 534-6.
75. Mutch W, Strudwick A, Roy S, Downie A. Parkinson disease: disability, review, and management. BMJ. 1986; 293: 675-77
76. Schrag A. Quality of life and depression in Parkinson’s disease. J neurol sci. 2006; 248: 151-7
77. Hanna KK & Alice Cronin-Golomb A. Impact of anxiety on quality of life in Parkinson’s disease. Parkinson’s dis. 2012; 640707 doi: 10.1155/2012/640707.
78. Movement Disorder society. MDS-UPDRS training program and exercise. Available at:
www.movementdisorders.org/updrs/home.php. Last accessed June 9, 2011.
79. Osuntokun BO, Bademosi O. Parkinsonism in the Nigerian African: a prospective study of 217 patients. East Afr Med J. 1979; 56: 597–607.
80. Slawek J, Derejko M, Lass P. Factors affecting the quality of life of patients with idiopathic Parkinson’s disease-a cross sectional study in an outpatient clinic attendees. Parkinsonism Relat Disord. 2005; 11: 465-8.
81. Saunders-Pullman R. Estrogens and Parkinson disease: neuroprotective, symptomatic, neither, or both? Endocrine. 2003; 21: 81–87.
82. Yahr MD, Duvoisin RC, Schear MJ, Barrett RE and Hoehn MM. Treatment of parkinsonism with levodopa. Arch. Neurol. 1969; 21: 343–54.
83. Martelli MF and MacMillan P. Zung Depression Scores for CVA Patients Enrolled in an Inpatient Rehabilitation Program. Paper presentation at the first annual Rehab Progress Symposium, Richmond, Virginia, 1989.
84. Jaunarajs KL, Angoa-Perez M, Kuhn DM, and Bishop C. potential Mechanisms underlying anxiety and depression in Parkinson’s disease: consequences of L-DOPA treatment. Neurosci Boibehav Rev. 2011; 25: 556-564
85. Damier P,Hirsch EC,Agid Y, and Graybiel AM The substantia nigra of the human brain. II.
Patterns of loss of dopamine-containing neurons in Parkinson’s disease. Brain. 1999.
122:1437–48.
86. Funkiewiez A, Ardouin C, Cools R, Krack P, Fraix V, Batir A, et al. Effects of levodopa and subthalamic nucleus stimulation on cognitive and affective functioning in Parkinson's
disease. Mov. Disord 2006; 21: 1656–62.
87. Kim HJ, Park SY, Cho YJ, Hong KS, Cho JY, Seo SY, et al. Non-motor symptoms in de novo Parkinson’s disease before and after dopaminergic treatment. J Neurol Sci. 2009; 287:
200–4.
88. Choi C, Sohn YH, Lee JH Kim J. The effect of long-term levodopa therapy on depression level in de novo patients with Parkinson's disease. J Neurol Sci 2000; 172: 12–6.
89. Rodriguez-Violante M, Cervantes-Arriaga A, Corona T, Martinez-Ramirez D, Morales-Briceno H, Martinez-Martin P. clinical determinants of Health related quality of life in Mexican Patients with PD. Arch Med Res. 2013; 44: 110-4
90. Higginson IJ, Gao W, Saleem TZ, Chaudhuri KR, Burmar R et al. Symptoms and quality of life in late stage Parkinson syndromes. A Longitudinal Community study of Predictive factors. Plos one 7 (11): e46327, doi: 10.13711. journal Pone. 0046327
91. Winter Y, Von Campenhausen S, Popov G, Reese JP Balzer-Geldsetzer M, Kukshina A, et al Social and clinical determinants of quality of life in Parkinson’s disease in a Russian cohort study. Parkinsonism Relat Disord. 2010; 16: 243-8.
92. Asimakopoulos P, Caslake R, Harris CE, Gordon JC, Taylor KS Counsell C. Changes in quality of life in people with Parkinson’s disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry. 2008; 79: 716-8.
93. Knipe MD, Wickremaractchi MM, Wyatt-Haines E, Morris HR, Ben-Shlomo Y. Quality of life in young- compared with late onset Parkinson’s disease. Mov Disord. 2011; 26: 2011-8